Onkologie. 2016:10(4):166-169 | DOI: 10.36290/xon.2016.036

Lobular breast cancer

Katarína Petráková

Klinika komplexní onkologické péče, MOÚ Brno

Invasive lobular carcinoma (ILC) is the second most common type of breast cancer. The majority of tumours are grade 2, have

positive oestrogen receptors (ER), low proliferation and no HER2 receptor amplification. During the first five years, ILC has a better

prognosis than invasive ductal carcinoma (IDC). In the 6–10 year follow-up interval, the overall survival rates are more favourable

for patients with IDC. Magnetic resonance imaging (MRI) has a higher sensitivity for ILC than mammography (MG); however, its

benefit is not unequivocal. In neoadjuvant studies, ILC is reported to have lower pCR rates, which has no effect on the overall

survival of patients. A high treatment response rate is achieved with neoadjuvant hormone therapy. Adjuvant chemotherapy is

recommended in patients with more than four positive nodes, negative oestrogen receptors, and grade 3.

Keywords: invasive lobular carcinoma, neoadjuvant chemotherapy, hormone therapy

Published: August 1, 2016  Show citation